Journal of psychopharmacology
-
J. Psychopharmacol. (Oxford) · Jan 1999
Case ReportsPostoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
We report a postoperative delirium expressed by a 49-year-old female patient during recovery from anaesthesia. Prominent features of the delirium, which lasted for nearly 2 days, included agitation, confusion, uncontrolled limb movements, abnormal ocular function, hypertension, pyrexia, brisk reflexes, ankle clonus and raised creatine kinase. The delirium did not respond to naloxone, diazepam or flumazenil. ⋯ During surgery, she was given morphine, which increases release of the neurotransmitter, serotonin, and ondansetron, which blunts neuronal release of dopamine. Although there is no clear explanation for the delirium, it had many features in common with problems associated with paroxetine withdrawal, the serotonin syndrome and the malignant neuroleptic syndrome. We offer several alternative explanations for this event, all of which rest on disruption of serotonergic and/or dopaminergic transmission and which could also involve inhibition by paroxetine of the P450 enzyme, CYP2D6, which metabolizes ondansetron.
-
J. Psychopharmacol. (Oxford) · Jan 1998
ReviewThe analgesic effects of selective serotonin reuptake inhibitors.
This paper endeavours to provide a critical clinical review of the use of selective serotonin reuptake inhibitors (SSRIs) in the management of pain. Case reports, placebo-controlled trials and trials comparing SSRIs with tricyclic antidepressants (TCAs) are considered. The analgesic effects of TCAs are well known and this review suggests that there is little evidence for their replacement by SSRIs in pain management. There are, at present, too few comparative drug trials to make a definitive statement, although the trend is clearly against SSRIs.